HB 1062
In CommitteeHouse
Biomarker testing coverage
Providing coverage for biomarker testing.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires private health insurers, public employee health plans, and Apple Health (Medicaid) in Washington to cover biomarker testing—such as genetic or protein tests used in cancer or other serious conditions—starting January 1, 2026, when supported by accepted medical evidence. It also requires plans to minimize patient inconvenience, like avoiding repeat tissue sampling.
- Starting January 1, 2026, private health insurers must cover biomarker testing when used for diagnosis, treatment, management, or monitoring of a disease—provided the test is supported by FDA approval, CMS guidelines, national clinical practice guidelines, or expert consensus statements.
- Public employee health plans (for state and local workers) must also cover biomarker testing under the same evidence-based criteria, effective January 1, 2026.
- Apple Health (Medicaid) must cover biomarker testing beginning January 1, 2026, with the state actively pursuing federal funding to help pay for it.
- Insurers and program administrators must ensure coverage minimizes disruptions to care—such as avoiding unnecessary repeat biopsies or specimen collection.
- The bill defines key terms: biomarker (e.g., gene mutations or protein levels), biomarker testing (e.g., blood or tissue tests including whole genome sequencing), consensus statements, and nationally recognized clinical practice guidelines.
Who is affected
- Private health plan enrollees — Residents with Washington-state-based health insurance plans (including individual, group, and employer-sponsored plans) who may need biomarker testing for conditions like cancer or other serious illnesses will gain coverage for these tests starting in 2026, without needing multiple tissue samples or causing care delays.
- Public employees and dependents — State and local government employees and their dependents enrolled in the state’s health plan will receive coverage for biomarker testing under the same standards as private plans beginning in 2026.
- Apple Health (Medicaid) enrollees — Low-income Washington residents enrolled in Apple Health (Medicaid) will gain access to biomarker testing coverage, with the state actively seeking federal matching funds to support this expansion.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (4)
The bill mandates coverage of biomarker testing for private insurers, public employee plans, and Apple Health when supported by accepted medical evidence—ensuring Washingtonians with serious illnesses (especially cancer patients) gain access to advanced diagnostic tools without requiring repeat invasive procedures, directly improving diagnostic accuracy and care continuity.
HealthcarePeopleRef: Sec. 1(2), Sec. 2(2), Sec. 3(2)By requiring plans to minimize patient inconvenience—specifically avoiding unnecessary repeat biopsies or biospecimen collection—the bill reduces physical trauma, emotional stress, and out-of-pocket costs for patients undergoing complex diagnostics, especially benefiting vulnerable populations like elderly or frail patients.
HealthcarePeopleRef: Sec. 1(3), Sec. 2(3), Sec. 3(3)The bill’s evidence-based coverage criteria—including FDA approval, CMS guidelines, nationally recognized clinical practice guidelines, and consensus statements—create a transparent, science-based standard that reduces arbitrary denials and helps ensure equitable access across payer types, reducing disparities in advanced diagnostics access.
HealthcarePeopleRef: Sec. 1(2)(d), Sec. 2(2)(d), Sec. 3(2)(d)The explicit inclusion of whole genome sequencing and multiplex panel tests in the definition of biomarker testing ensures coverage of cutting-edge, comprehensive diagnostic tools—potentially improving early detection and personalized treatment for serious conditions, especially for patients with rare or hard-to-diagnose diseases.
HealthcarePeopleRef: Sec. 1(4)(b), Sec. 2(4)(b), Sec. 3(4)(b)
Potential Concerns (1)
The bill requires Apple Health (Medicaid) to cover biomarker testing beginning in 2026, but the state must seek federal matching funds to offset costs—meaning coverage is contingent on federal approval and funding availability, creating uncertainty about timely, full implementation for low-income enrollees who rely on Medicaid for essential care.
HealthcarePeopleRef: Sec. 3(4)
Who Is Most Affected
Cancer patients and individuals with serious chronic illnesses gain direct access to advanced diagnostics without prior barriers—reducing diagnostic delays, repeat procedures, and out-of-pocket costs. This is especially impactful for Medicaid enrollees who previously faced higher rates of coverage denial for advanced testing.
Low-income Apple Health enrollees benefit significantly from expanded access to advanced diagnostics, but coverage success depends on federal matching funds—introducing uncertainty. If federal funding stalls, the state may face budget pressure or delayed implementation, potentially limiting real-world access despite the mandate.
Private insurers must absorb new coverage costs but can pass some to employers or enrollees via premiums. However, the evidence-based standard reduces administrative burden and arbitrary denials, potentially lowering long-term costs through better-targeted care. Small employers may face modest premium increases, while large employers may see minimal impact due to risk-pooling.
Public employees gain parity with private-sector coverage for advanced diagnostics, improving equity across public and private plans. However, state budget planners must account for increased plan costs—potentially affecting future contributions or benefits if federal Apple Health matching funds fall short.
Diagnostics labs and genomic testing companies may see increased demand and reimbursement certainty, but the bill does not set payment rates—so reimbursement levels and speed of adoption depend on payer implementation. Large national labs may benefit more than small local labs due to scale and negotiating power.